Investor Presentation

Investor Presentation July 2026 Beta Drugs at a Glance: Scale, Reach and Sustained Financial Strength 20+ 26+ 246+ 3 State-of-the-art Countries Served Years of Experience Global Clients Manufacturing facilities Globally 280+ 220+ 2 66+ Dossiers Registered Specialty Therapies SKU’s Territory Managers Globally (Oncology & IVF) 27% 25% 29% 5 Year Revenue CAGR 5 Year EBITDA CAGR 5 Year PAT CAGR Consistent Track Record of High Growth 0.60x Debt-to-Equity ROCE Figures as on FY26 2 Company Overview Company Overview: Building a Diversified Specialty Pharma Franchise • Established in 2005 as part of the Adley Group, by Mr. Vijay Kumar Batra, Consolidated Revenue (INR Mn) & EBITDA Margin (%) Beta Drugs Ltd. (BETA) is a specialty pharmaceutical company dedicated 3,848 3,624 to improving cancer care through innovative therapies. 2,957 • The company has a well-diversified business model supported by branded 21.83% formulations, CMO services and APIs, with expansion into other specialty 1,255 20.75% 20.59% 19.67% therapies like IVF enhancing future growth prospects. • Offers a comprehensive oncology portfolio under the "Adley" brand, FY24 FY25 FY26 Q1-FY27 spanning chemotherapy, targeted and hormonal therapies across multiple dosage forms, including tablets, capsules, injections, and lyophilized injections. • BETA is a trusted partner to leading healthcare institutions, with products Segment Wise Sales FY26 available across 85%+ of corporate and government hospitals in India. Exports, • The company exports products across 25+ countries, supported by a growing base of product registrations and regulatory filings in international CMO, 39% markets. • Manufacturing operations supported by 3 WHO-GMP certified facilities Domestic Branded with one of the plants having ANVISA,INVIMA & COFEPRIS certifications, Formulations, catering to domestic and international demand across multiple product 36% API, 7% categories. Business Verticals: A Diversified Revenue Mix Across Four Pillars Domestic Branded Formulations Exports CMO API Revenue Contribution 18% 39% 7% Revenue Revenue Revenue Contribution Contribution Contribution Oncology IVF* Dermatology * IVF revenues has been consolidated in the Domestic Branded Formulations from FY27 following NivianLifesciences becoming a subsidiary in April 2026 All figures as on FY26 5 Globally Accredited Manufacturing Facilities with Large Installed Capacities Beta Drugs Ltd India Formulation Adley Lab India API Plant Adley Formulations India Plant Formulation Plant Certifications: CCeerrttiiffiiccaattiioonnss:: Certifications: Location: Nandpur, Solan, Himachal Location: Derabassi, Location: Barotiwala, Solan, Himachal Pradesh, India Punjab, India Pradesh, India Annual Production Capacity: Annual Production Capacity: Annual Production Capacity: • Production Line 1 –60 TPA • 3.0 Mn Liquid Injections • 1.5 –3.3 Mn Liquid Injections • Production Line 2 –30 TPA • 0.5 Mn Lyophilized Injections • 1.0 –6.3 Mn Lyophilized Injections • 50 Mn Tablets • 15.0 –35.0 Mn Tablets • 10 Mn Capsules • 5.0 –8.0 Mn Capsules • 9 Mn Prefilled Syringe Fillings Capacity Utilization 67.30% Capacity Utilization 79.42% Capacity Utilization 69.93% Robust R&D Capabilities Supporting Future Growth 80 13 25% 2 Total Products Developed New Products Patents Products in FY25 &FY26 Contribution in FY26 • BETA is among the select Indian oncology pharmaceutical companies that has strong commitment to research, innovation and product development. Track Record of Product Innovation • It has strong focus on Novel Drug Delivery Systems (NDDS), including Liposomes, Nanoparticles and Microparticle technologies. • The company is pioneer in Nano-Albumin Bound Paclitaxel, Ready-to-Use Docetaxel and Gemcitabine formulations. • A patient-centric R&D approach which focuses on improving efficacy, 10 safety and treatment outcomes. Successful Product Launches FY26 FY21-FY22 FY23-FY24 FY25-FY26 FY27-FY29 Figures as on FY26 7 Strong Global Presence Across Diverse Geographies LATAM MENA Africa APAC • Belize • Algeria • Ethiopia • India • Brazil • Azerbaijan • Ivory De • Kazakhstan • Caracas • Belarus Cote • Mangolia • Chile • Egypt • Kenya • Myanmar • Columbia • Georgia • Nigeria • Nepal • Costa Rica • Jordan • Tanzania • Philippines • Ecuador • Mauritius • Uganda • Russia • El Salvador • Morocco • Zimbabwe • Sri Lanka • Guatemala • Syria • Uzbekistan • Honduras • Yemen • Mexico • Nicaragua • Panama • Peru • Saint Martin • Venezuela Geography Wise Sales FY26 Region Wise Export Distribution FY26 Dossier No of registrations Registration Approved Products Registrations till date* Pipeline APAC, Domestic, LATAM 52 90 220 32% APAC 63 105 105 MENA 17 26 157 AFRICA, LATAM, AFRICA 29 59 53 42% 19% CIS 5 0 88 Exports, Total 166 280 623 MENA, 7% * Excludes Approved Products Figures as on FY26 Key Milestones in the Company's Growth Journey 1985 2007 2011 2015 2017 2025 Laid the Entered into Foray into Developed • Received SME • Awarded in Forbes Under a billion for 3 foundation of Oncology the in-house Excellence Award Adley Group by Market international Albumin • Listed in NSE SME consecutive years – 2023, 2024 & 2025 Late Shri. Vijay market bound Platform Batra Paclitaxel • Commenced In-house • Migrated from NSE SME to NSE Mainboard. API Plant -Adley Labs 2005 2008 2014 2016 2024 2026 Secures INR 117 Cr Incorporation Setup the first Setup a new state of Received Entered into IVF via CCDs from of Beta Drugs Oncology Unit in the art Certificate of Business with the global institutional Ltd Adley manufacturing Good acquisition of investors Formulations Pvt facility for oncology Manufacturing 66.09% in Nivian HealthQuadand Ltd formulations in Practice from Life Sciences Pvt Tanas Capital for Nandpur Republic of Kenya Ltd future growth Seasoned Leadership Team Driving Strategy, Growth and Governance Mr. Rahul Mr. Varun Mr. Ashutosh Batra Batra Shukla Joint Managing Director Executive Director Chairman and Managing Director He holds Master of Science degree in Business and He is the Joint Managing Director of our Company. He is a director sales & marketing. He handles Management from University Strathclyde Scotland. He holds Degree in Business Management from domestic and international market. He holds His Scope of work includes managing Marketing and Toronto Canada. His Scope of work includes executive MBA degree fromSymbiosis International Sales segment of the Company. Leading the group's monitoring Production Department and Export sales University,Pune.Heishavingmorethan20yearsof domestic growth andcorporate strategy with afocus oftheCompany. experience of sales & marketing in top onownbrands. pharmaceuticalcompanies. Mr. Balwant Mr. Nipun Ms. Rajni Singh Arora Brar Whole Time Director Company Secretary Chief Financial Officer He holds a PGDPM in HR & IR from DAV College of He is a Chartered Accountant, Company Secretary She holds a Bachelor's degree in Commerce from Management, Chandigarh. He brings 19 years of and Cost Accountant with expertise in financial Punjab University and a Post Graduate Diploma in experience in the pharmaceutical industry and is management, accounting, auditing, taxation, and Business Administration from Symbiosis Centre. She responsible for managing the overall affairs of the statutory compliance. He plays a key role in brings strong expertise in corporate governance, Company, including technical operations and plant strengthening the Company's financial governance regulatory compliance, secretarial practices and managementacrosstheBaddifacilities. andensuringregulatoryadherence. stakeholdermanagement. Independent Board Of Directors: Strong Governance and Oversight Mr. Sanjay Mr. Ajay Mrs. Monica Sehgal Mahipal Jain Independent Director Independent Director Independent Director He is a Partner at HealthQuad, overseeing She is M.S.Ophthalmologist in 2000. She is having He is a Post graduate in Commerce, having approx investments and portfolio management, with 20+ an exp [Showing first 8,000 characters — download PDF for full document]